Small molecule inhibitors as probes for estrogen and androgen receptor action

David J Shapiro, Chengjian Mao, Milu T. Cherian

Research output: Contribution to journalShort survey

Abstract

Because activated estrogen (ER) and androgen (AR) receptors stimulate cell proliferation in breast and prostate cancer, inhibiting their actions represents a major therapeutic goal. Most efforts to modulate ER and AR activity have focused on inhibiting the synthesis of estrogens or androgens or on the identification of small molecules that act by competing with agonist hormones for binding in the ligand-binding pocket of the receptor. An alternative approach is to implement screens for small molecule inhibitors that target other sites in the pathway of steroid receptor action. Many of these second-site inhibitors directly target ER or AR; others have still unknown sites of action. Small molecule inhibitors that target second sites represent new leads with clinical potential; they serve as novel modulators of receptor action; and they can reveal new and as yet unidentified interactions and pathways that modulate ER and AR action.

Original languageEnglish (US)
Pages (from-to)4043-4048
Number of pages6
JournalJournal of Biological Chemistry
Volume286
Issue number6
DOIs
StatePublished - Feb 11 2011

Fingerprint

Androgen Receptors
Estrogen Receptors
Androgens
Estrogens
Molecules
Steroid Receptors
Cell proliferation
Modulators
Prostatic Neoplasms
Cell Proliferation
Hormones
Breast Neoplasms
Ligands
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Small molecule inhibitors as probes for estrogen and androgen receptor action. / Shapiro, David J; Mao, Chengjian; Cherian, Milu T.

In: Journal of Biological Chemistry, Vol. 286, No. 6, 11.02.2011, p. 4043-4048.

Research output: Contribution to journalShort survey

Shapiro, David J ; Mao, Chengjian ; Cherian, Milu T. / Small molecule inhibitors as probes for estrogen and androgen receptor action. In: Journal of Biological Chemistry. 2011 ; Vol. 286, No. 6. pp. 4043-4048.
@article{1ebf3bb635ca4f51b8daad8bfc5ec5c6,
title = "Small molecule inhibitors as probes for estrogen and androgen receptor action",
abstract = "Because activated estrogen (ER) and androgen (AR) receptors stimulate cell proliferation in breast and prostate cancer, inhibiting their actions represents a major therapeutic goal. Most efforts to modulate ER and AR activity have focused on inhibiting the synthesis of estrogens or androgens or on the identification of small molecules that act by competing with agonist hormones for binding in the ligand-binding pocket of the receptor. An alternative approach is to implement screens for small molecule inhibitors that target other sites in the pathway of steroid receptor action. Many of these second-site inhibitors directly target ER or AR; others have still unknown sites of action. Small molecule inhibitors that target second sites represent new leads with clinical potential; they serve as novel modulators of receptor action; and they can reveal new and as yet unidentified interactions and pathways that modulate ER and AR action.",
author = "Shapiro, {David J} and Chengjian Mao and Cherian, {Milu T.}",
year = "2011",
month = "2",
day = "11",
doi = "10.1074/jbc.R110.203026",
language = "English (US)",
volume = "286",
pages = "4043--4048",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "6",

}

TY - JOUR

T1 - Small molecule inhibitors as probes for estrogen and androgen receptor action

AU - Shapiro, David J

AU - Mao, Chengjian

AU - Cherian, Milu T.

PY - 2011/2/11

Y1 - 2011/2/11

N2 - Because activated estrogen (ER) and androgen (AR) receptors stimulate cell proliferation in breast and prostate cancer, inhibiting their actions represents a major therapeutic goal. Most efforts to modulate ER and AR activity have focused on inhibiting the synthesis of estrogens or androgens or on the identification of small molecules that act by competing with agonist hormones for binding in the ligand-binding pocket of the receptor. An alternative approach is to implement screens for small molecule inhibitors that target other sites in the pathway of steroid receptor action. Many of these second-site inhibitors directly target ER or AR; others have still unknown sites of action. Small molecule inhibitors that target second sites represent new leads with clinical potential; they serve as novel modulators of receptor action; and they can reveal new and as yet unidentified interactions and pathways that modulate ER and AR action.

AB - Because activated estrogen (ER) and androgen (AR) receptors stimulate cell proliferation in breast and prostate cancer, inhibiting their actions represents a major therapeutic goal. Most efforts to modulate ER and AR activity have focused on inhibiting the synthesis of estrogens or androgens or on the identification of small molecules that act by competing with agonist hormones for binding in the ligand-binding pocket of the receptor. An alternative approach is to implement screens for small molecule inhibitors that target other sites in the pathway of steroid receptor action. Many of these second-site inhibitors directly target ER or AR; others have still unknown sites of action. Small molecule inhibitors that target second sites represent new leads with clinical potential; they serve as novel modulators of receptor action; and they can reveal new and as yet unidentified interactions and pathways that modulate ER and AR action.

UR - http://www.scopus.com/inward/record.url?scp=79953005347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953005347&partnerID=8YFLogxK

U2 - 10.1074/jbc.R110.203026

DO - 10.1074/jbc.R110.203026

M3 - Short survey

C2 - 21149443

AN - SCOPUS:79953005347

VL - 286

SP - 4043

EP - 4048

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 6

ER -